Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Schlumberger NV (SLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Schlumberger NV — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Schlumberger NV trades at $47.41 (market cap $69.40B). The key difference: Schlumberger NV is far larger — about 15.5× ACADIA Pharmaceuticals Inc.'s market cap, and Schlumberger NV pays a 2.54% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SLB | |
|---|---|---|
Market Cap | $4.49B | $69.40B |
Sector | Health | Energy |
52-Week High | $28.06 | $58.01 |
52-Week Low | $20.06 | $31.72 |
Enterprise Value | $3.69B | $77.62B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
SLB trades at $46.42, up 2.86% today, amid a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $0.52, exceeding the $0.508 estimate, and holds a strong analyst consensus with a $63.00 price target. Recent news highlights a seven-year digital innovation contract in Kuwait, expanding its energy technology footprint. Cash flow from operations remains robust at $6.49B for 2025, though net cash flow was negative due to significant financing activities.
The outlook is cautiously optimistic, supported by solid fundamentals and growth initiatives in digital and AI, but faces headwinds from oil price volatility and a recent decline in net income margin to 9.26%. The stock presents a potential opportunity given its valuation discounts to analyst targets, though macroeconomic risks and sector cyclicality warrant attention.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
